Chronic myeloid leukaemia - The choice of therapy and future perspectives

Angelo M. Carella, Clara Dellepiane, Davide Lovera, Adalberto Ibatici, Chiara Ghiggi, Andrea Carella, Germana Beltrami

Research output: Contribution to journalArticle

Abstract

Recently, the advent of imatinib has opened a new era in the treatment of chronic myeloid leukaemia (CML), leading to an impressive increase in overall survival rates. Today, many CML patients can expect to survive, if properly managed, likely similar to the general population. Recent progresses in CML stem cell biology have identified new leukogenetic pathways and therapeutic strategies that can be used to target the CML stem cell compartment. These studies have opened new perspectives in CML therapy and have highlighted major strategies for treating, and possibly eradicating, CML in the upcoming years.

Original languageEnglish
Pages (from-to)25-29
Number of pages5
JournalEuropean Oncology and Haematology
Volume11
Issue number1
DOIs
Publication statusPublished - Jun 1 2015

    Fingerprint

Keywords

  • Chronic myeloid leukaemia
  • New therapeutic strategies
  • Stem cell biology
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Carella, A. M., Dellepiane, C., Lovera, D., Ibatici, A., Ghiggi, C., Carella, A., & Beltrami, G. (2015). Chronic myeloid leukaemia - The choice of therapy and future perspectives. European Oncology and Haematology, 11(1), 25-29. https://doi.org/10.17925/EOH.2015.11.01.25